Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

The semi-finals of Manx Hockey Association’s men’s and women’s cup, plate and bowl competitions took place on Saturday, with ...

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

Find insight on Fresnillo, the copper market, Australian mining, and more in the latest Market Talks covering Basic Materials ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Today, Benzinga's options scanner identified 8 options transactions for Hut 8. This is an unusual occurrence. The sentiment ...

Cardinal Energy Ltd. (TSX: CJ) ("Cardinal" or the "Company") is pleased to announce that it has completed its previously ...

Clover Health Investments (NASDAQ:CLOV – Free Report) had its target price raised by Canaccord Genuity Group from $4.20 to $4.50 in a research report report published on Monday morning,Benzinga ...

The looming end to Australia’s $40bn hybrid securities market represents a big opportunity for stockbroking veteran Geoff ...

Revenue for Q4 2024 reached $100.9 million, up 38% year-over-year, driven by a 17% increase in MTMs and an 18% rise in ARPU. Adjusted EBITDA for the quarter was $33.4 million, marking a 35% sequential ...